Arrow Financial's 15min chart shows KDJ Death Cross and Bearish Marubozu.
PorAinvest
miércoles, 17 de septiembre de 2025, 11:47 am ET1 min de lectura
AROW--
At Cryo-Cell International, Chairman and Co-CEO David Portnoy made a significant purchase of 42,900 shares on Wednesday, September 12, 2025. The shares were bought at a cost of $4.43 each, totaling an investment of $189,986. This latest buy follows several previous purchases by Portnoy, totaling $285,581 at an average price of $4.44 per share over the past year. As of Friday, September 14, 2025, Cryo-Cell International's stock has traded down by approximately 3.5% on the day, indicating a slight decline in share value [1].
Arrow Financial also saw insider buying activity on Wednesday, September 12, 2025. The company's Chief Financial Officer, Penko Krassimir Ivanov, purchased 5,000 shares at a cost of $29.10 each, totaling $145,499. This latest purchase builds upon Ivanov's previous investments in AROW, amounting to $391,248 over the past twelve months at an average price of $29.14 per share. As of Friday, September 14, 2025, Arrow Financial's stock has traded off by approximately 0.5% on the day, showing a minimal decrease in share value [1].
While these insider buys suggest a positive outlook from the executives, it is essential to consider the broader market conditions. For instance, Arrow Financial's 15-minute chart triggered a KDJ Death Cross and a Bearish Marubozu on September 17, 2025, at 11:45, indicating a shift in momentum towards the downside and a potential for further price decrease. Sellers are currently in control of the market, suggesting that bearish momentum may continue .
CCEL--
Arrow Financial's 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu at 09/17/2025 11:45, indicating a shift in momentum towards the downside and a potential for further price decrease. Sellers are currently in control of the market, and it is likely that bearish momentum will continue.
In the realm of financial markets, insider buying can often signal a positive outlook on a company's future prospects. Two notable insider purchases were reported recently, shedding light on the sentiments of key executives at Cryo-Cell International (CCEL) and Arrow Financial (AROW).At Cryo-Cell International, Chairman and Co-CEO David Portnoy made a significant purchase of 42,900 shares on Wednesday, September 12, 2025. The shares were bought at a cost of $4.43 each, totaling an investment of $189,986. This latest buy follows several previous purchases by Portnoy, totaling $285,581 at an average price of $4.44 per share over the past year. As of Friday, September 14, 2025, Cryo-Cell International's stock has traded down by approximately 3.5% on the day, indicating a slight decline in share value [1].
Arrow Financial also saw insider buying activity on Wednesday, September 12, 2025. The company's Chief Financial Officer, Penko Krassimir Ivanov, purchased 5,000 shares at a cost of $29.10 each, totaling $145,499. This latest purchase builds upon Ivanov's previous investments in AROW, amounting to $391,248 over the past twelve months at an average price of $29.14 per share. As of Friday, September 14, 2025, Arrow Financial's stock has traded off by approximately 0.5% on the day, showing a minimal decrease in share value [1].
While these insider buys suggest a positive outlook from the executives, it is essential to consider the broader market conditions. For instance, Arrow Financial's 15-minute chart triggered a KDJ Death Cross and a Bearish Marubozu on September 17, 2025, at 11:45, indicating a shift in momentum towards the downside and a potential for further price decrease. Sellers are currently in control of the market, suggesting that bearish momentum may continue .
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios